Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck& Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news